Scope and Claims Analysis for US Patent 10,617,696: Oral Capsule Liquid/Semi-Solid Testosterone Undecanoate Formulation (Oleic Acid, Kolliphor EL, Borage Seed Oil, Peppermint Oil)
US Patent 10,617,696 is a formulation patent with a claim structure that is tightly tied to (i) an oral capsule dosage form and (ii) a specific liquid or semi-solid intraluminal fill composition by weight, anchored to testosterone undecanoate and a defined excipient package (oleic acid, polyoxyethylene(40) hydrogenated castor oil, borage seed oil, peppermint oil). The claim scope is narrow at the excipient and percent-by-weight level, and it is most directly infringed by products that replicate the exact capsule-with-fill configuration and the exact composition ranges implied by the stated percentages.
What exactly does US Patent 10,617,696 claim for testosterone undecanoate capsules?
Short answer: Claim 1 requires an oral capsule that contains a liquid or semi-solid pharmaceutical formulation with a defined by-weight composition: 19.8% testosterone undecanoate, 51.6% oleic acid, 16.1% polyoxyethylene(40) hydrogenated castor oil (typically “HCO-40” or “Kolliphor EL”), 10% borage seed oil, and 2.5% peppermint oil.
Key claim elements (constraint-by-constraint)
-
Dosage form / device element
- “An oral composition comprising a capsule”
- “and a liquid or semi-solid pharmaceutical formulation within the capsule”
Practical implication: the claim does not read on tablets, sachets, minitablets, or any non-capsule delivery format unless the product uses a capsule containing a liquid or semi-solid fill.
-
In-capsule formulation characterization
- The formulation is defined by its ingredient presence and specific weight percentages.
Practical implication: the patent’s strongest infringement hook is exact or effectively equivalent fill composition matching the claimed weight fractions.
-
Actives and excipient package
- Active: testosterone undecanoate
- Oil phase and solubilizers: oleic acid
- Surfactant/solubilizer: polyoxyethylene(40) hydrogenated castor oil
- Additional oils/aromatics: borage seed oil and peppermint oil
Claim 1 composition locked to five ingredients
| Ingredient |
Claimed wt. % |
Role implied by composition |
| Testosterone undecanoate |
19.8% |
lipophilic androgen ester |
| Oleic acid |
51.6% |
carrier oil, penetration/lipolysis support |
| Polyoxyethylene (40) hydrogenated castor oil |
16.1% |
surfactant/solubilizer |
| Borage seed oil |
10% |
supplemental oil phase |
| Peppermint oil |
2.5% |
flavor/aroma, possible excipient function |
Scope consequence: With five components and five exact percentages, the claim is not framed as a range claim (based on the excerpt provided). If the issued claim uses exact numbers, design-arounds commonly revolve around changing one or more wt. % values outside the claimed point values or using alternative oils/surfactants.
What this claim does not cover (based on the provided claim text)
- It does not appear to cover alternate testosterone esters (e.g., testosterone enanthate).
- It does not appear to cover alternate capsule fills using different surfactants (polysorbates, Cremophor alternatives) unless they still meet the claim language as written.
- It does not appear to cover non-liquid, solid, or enteric-coated microstructures unless the “liquid or semi-solid” condition is met.
How narrow is the claim based on the formulation percentages?
Short answer: It is narrow. The claim reads like a single, point-specific recipe.
Why “percent-by-weight” language drives narrow scope
When a formulation claim recites exact percentages for each component, it typically:
- limits infringement to products whose quantitative composition matches the claim recitation, or
- forces courts toward literal interpretation unless the claim includes tolerance language or synonyms that broaden the quantification.
If the issued claim text is exactly as provided, then:
- changing oleic acid from 51.6% to 49% or 54% can be a direct non-infringement lever.
- substituting borage seed oil (or modifying the oil’s composition with different seed oils) can be a non-infringement lever.
- swapping peppermint oil for another essential oil can avoid literal match.
Design-around candidates at the claim-grammar level
At a high level, any product that differs in at least one of the five components or its claimed wt.% point is a plausible design-around, assuming no doctrine-of-equivalents overlap is credited for excipient-level differences. The closest “at-risk” scenario is a product that keeps all five ingredients and stays extremely close to the claimed wt.% values.
How does the claim compare with other testosterone undecanoate oral lipid formulation patterns?
Short answer: The claim’s uniqueness is the combination of (i) a high oleic acid fraction, (ii) polyoxyethylene(40) hydrogenated castor oil as the surfactant, and (iii) borage seed oil and peppermint oil as added components.
Typical industry formulation architecture for oral T undecanoate
Oral testosterone undecanoate products generally use:
- lipids to improve intestinal absorption,
- one or more solubilizers/surfactants,
- and often additional excipients to influence tolerability, stability, and capsule fill properties.
What sets this patent apart is the explicit recipe including borage seed oil and peppermint oil at defined wt.% values.
Competitive implication
Formulators that follow “standard” lipid-surfactant frameworks may still avoid this patent if they omit borage seed oil and/or peppermint oil, or swap the surfactant family.
What patents protect the same testosterone undecanoate capsule approach in the US?
Short answer: A complete US landscape analysis for the same product class requires the full patent family (published applications, continuation/divisional members, and related Orange Book-listed patents). No additional patent numbers, assignees, citations, or family members are provided in the input, so only the scope of US 10,617,696 can be analyzed from the supplied claim text.
What claim strength does US 10,617,696 have for infringement?
Short answer: Strength is moderate-to-high against exact-copy formulations, and lower against “similar” lipid formulations that change excipients or wt.% points.
Infringement risk is driven by composition matching
Because the claim defines a precise wt.% recipe, the principal infringement questions become:
- Does the accused product use testosterone undecanoate (not another ester)?
- Is the delivery via capsule containing a liquid/semi-solid fill?
- Does it contain the specific excipient set including borage seed oil and peppermint oil?
- Does the product match the claimed wt.% composition of all five ingredients?
Evidence typically decisive in formulation disputes
For formulation patents like this, the claim usually turns on:
- product label and manufacturing specs (if accessible),
- formulation composition test results (GC/HPLC for oils and surfactants, assay for testosterone undecanoate),
- and batch-to-batch variability relative to the claimed recipe.
When does US 10,617,696 lose exclusivity?
Short answer: This cannot be determined from the provided information. Patent term depends on the filing date (35 USC 154), adjustments (OAs), and possible terminal disclaimers. The input provides only the patent number and claim excerpt, not filing/priority dates.
What Orange Book status would US 10,617,696 likely have for a testosterone undecanoate product?
Short answer: Not determinable from the provided input. Orange Book coverage depends on whether the patent was listed for a specific NDA and whether it is a composition-of-matter, method-of-use, or formulation patent listed for a particular strength and dosage form.
How does the patent landscape affect generic entry for oral testosterone undecanoate capsules?
Short answer: Generic entry risk hinges on whether a generic product must (i) exactly match the claimed capsule fill recipe or (ii) can seek regulatory workarounds that avoid literal infringement. Without the broader landscape and listing status, only the mechanism can be stated: a generic entering with a different excipient package or altered wt.% values may reduce patent exposure to US 10,617,696.
Paragraph IV strategy implications (composition patents)
If US 10,617,696 is listed for a particular reference product, generic challengers typically evaluate:
- whether their formulation matches the exact claim recipe,
- whether the claim is invalid over prior art recipes, and
- whether a non-infringement position can be sustained by excipient substitution or wt.% changes.
What is the likely patent family scope for US 10,617,696?
Short answer: Not determinable from the provided input. Family scope depends on continuation/divisional/published counterpart applications, which are not supplied.
How does US 10,617,696 compare with potential method-of-use or process patents?
Short answer: The claim provided is a composition/formulation claim. It does not appear to be a method-of-treatment or manufacturing process claim, based on the excerpt.
Practical consequence
- A competitor could potentially avoid this formulation claim by changing formulation composition while still using the same clinical regimen.
- If there are separate method-of-use or process patents in the same family or related families, those could still constrain entry even if this formulation claim is designed around.
Key takeaways
- US 10,617,696 claim 1 is a tightly bounded formulation claim requiring an oral capsule containing a liquid or semi-solid fill with a defined five-ingredient, exact wt.% recipe.
- The strongest infringement path is an accused product that matches all five ingredients and the stated wt.% values: 19.8% testosterone undecanoate, 51.6% oleic acid, 16.1% polyoxyethylene(40) hydrogenated castor oil, 10% borage seed oil, 2.5% peppermint oil.
- Literal infringement risk drops materially if a generic or branded product alters any ingredient identity (not using borage seed oil or peppermint oil) or changes wt.% values away from the claimed recipe.
- A full US patent landscape for testosterone undecanoate capsule formulations, including related patents, Orange Book listings, and expiration/exclusivity dates, cannot be constructed from the provided input alone.
FAQs
1) Would a testosterone undecanoate capsule that replaces borage seed oil avoid infringement of US 10,617,696?
If it does not include “borage seed oil” as a component in the claimed wt.% formulation, it does not meet the claim’s ingredient limitation as written.
2) Does US 10,617,696 cover tablets or only capsules?
The claim text provided requires “a capsule” and a formulation within the capsule, so non-capsule dosage forms do not satisfy that element.
3) If a product uses the same excipients but different wt.% values, does it still infringe?
Under literal claim construction, changing the wt.% values away from the claimed percentages is a direct non-infringement lever if the claim uses exact recitations without tolerance.
4) Can a generic avoid the patent by using a different surfactant than polyoxyethylene(40) hydrogenated castor oil?
Yes, if the formulation does not contain the claimed surfactant as recited in the claim.
5) Is this patent a composition-of-matter or a method-of-use claim?
Based on the provided claim 1 text, it is a composition/formulation claim focused on an oral capsule containing a specified liquid or semi-solid formulation.
References
(No sources were provided in the input to cite.)
